Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study
Qiang Cao, Jinyi Zhu, Xinyan Wu, Jiapeng Li, Yuquan Chen, Yanwei You, Xiaochen Li, Xufeng Huang, Yujie Zhang, Rizhu Li, Dan Han
Abstract
The IPCGOR combined with IL-2 regimen shows promising efficacy and a tolerable safety profile for advanced NSCLC. These findings suggest its potential as a reference for treating advanced NSCLC. However, the study's retrospective nature and single-center design pose limitations. Future research should focus on prospective studies, randomized controlled trials, and long-term outcome assessments, particularly in diverse patient subgroups, to further validate and refine the clinical application of this regimen.
Topics & Concepts
MedicineRegimenLung cancerInternal medicineOncologyRetrospective cohort studyGemcitabineOxaliplatinResponse Evaluation Criteria in Solid TumorsAdverse effectChemotherapyChemotherapy regimenSurgeryCancerProgressive diseaseColorectal cancerLung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers